P-GP170、LRP与Ki-67在甲状腺乳头状癌中的表达及临床意义  

Expression and Clinical Significance of P-GP170, LRP and Ki-67 in Thyroid Carcinoma

作　　者：成继民[1] 贺占国[1] 刘艳丽[1] 郭宏[1] 陈静[1] 

机构地区：[1]白求恩国际和平医院病理科,石家庄050082

出　　处：《肿瘤防治研究》2004年第9期542-544,共3页Cancer Research on Prevention and Treatment

摘　　要：目的　检测多药耐药基因蛋白P 糖蛋白 (P GP170 )和肺耐药蛋白 (LRP)与抗核抗体Ki 6 7在甲状腺乳头状癌中的表达及临床意义。方法　采用免疫组化SP法检测P GP170、LRP、Ki 6 7在 6 4例甲状腺乳头状癌和 2 0例甲状腺腺瘤中的表达。结果　 3种抗体在甲状腺乳头状癌中均呈高表达 ,在甲状腺腺瘤中呈低表达。与甲状腺腺瘤相比有显著性差异 (P <0 .0 1)。P GP170、LRP、Ki 6 7三者呈显著相关性 (LRP与Ki 6 7r =0 .4 2 ,LRP与P GP170r =0 .4 2 ,Ki 6 7与P GP170r =0 .6 5 ,P <0 .0 1)。结论甲状腺乳头状癌标记指数高、耐药性强、化疗敏感性低。在化疗中同时给予耐药抑制剂 ,可以提高化疗敏感性和化疗效果。Objective To investigate expression and clinical significance of P-GP170 (P-glyco-protein, P-GP170),LRP(Lung-Resistance-Protein, LRP) and anti-nuclear antigen Ki-67 in papillary thyroid tumors.Methods SP immunohistochemical technique was used to detect expression of P-GP170, LRP and Ki-67 in 64 cases of papillary thyroid carcinoma and 20 cases of thyroid adenoma.Results P-GP170, LRP and Ki-67 all have high level expression in papillary thyroid carcinoma but low level expression in thyroid adenoma. The difference is statistically significant (P<(0.01)). The positive rate of P-GP170 and LRP in papillary thyroid carcinoma both were (93.75%). The LI (lableling index, LI) of Ki-67 in thyroid carcinoma was (55.94)±(37.62). The relation of P-GP170, LRP and Ki-67 was notably significant (LRP vs Ki-67 r=(0.42), LRP vs P-GP170, r=(0.42), Ki-67 vs P-GP170, r=(0.65), P<(0.01)).Conclusion To choose suitable inhibitors of multydrug resistance protein in the clinical chemotherapy of papillary thyroid carcinoma may improve the effect of chemotherapy of thyroid carcinoma for the high level of LI, strong multydrug resistance and poor sensitivity to the chemotherapeutic agents in papillary thyroid carcinoma.

关 键 词：甲状腺乳头状癌 P-GP170 LRP KI-67 

分 类 号：R736.1[医药卫生—肿瘤]